Janus kinase 2 inhibitors in myeloproliferative disorders

Author： Lucia Eugenio   Recchia Anna Grazia   Gentile Massimo   Bossio Sabrina   Vigna Ernesto   Mazzone Carla   Madeo Antonio   Morabito Lucio   Gigliotti Vincenzo   Stefano Laura De   Caruso Nadia   Servillo Pasquale   Franzese Stefania   Bisconte Maria Grazia   Gentile Carlo   Morabito Fortunato  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.1, 2011-01, pp. : 41-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

By Rosenthal Allison   Mesa Ruben A  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 9, 2014-06 ,pp. : 1265-1276

Informa Healthcare

Access to resources Recommend Favorite

Quantitative Assay for Janus Kinase 2 (JAK2) Mutation in Chinese Patients with Chronic Myeloproliferative Disorders

By Shen Y-M   Chao H-Y   Zhang R   Feng Y-F   Cen J-N   Yao L   Shen H-J   Zhu Z-L   Xue Y-Q  

The Journal of International Medical Research, Vol. 37, Iss. 1, 2009-01 ,pp. : 37-46

Field House Publishing

Access to resources Recommend Favorite

Investigational Janus kinase inhibitors

By Tam Constantine S  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 687-699

Informa Healthcare

Access to resources Recommend Favorite

Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening

By  

Mini Reviews in Medicinal Chemistry, Vol. 17, Iss. 3, 2017-01 ,pp. : 268-294

Bentham Science Publishers

Access to resources Recommend Favorite

Pyrrolo[2,3]pyrimidine inhibitors of Janus kinase 3 protein tyrosine kinase

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 7, 2003-07 ,pp. : 1087-1092

Informa Healthcare

Access to resources Recommend Favorite